Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades
Reuben Gregg Brewer, The Motley FoolSun, February 22, 2026 at 8:07 PM UTC
0
Key Points -
Novartis is a large drugmaker with a wide-ranging portfolio.
Like all drugmakers, it faces the challenge of patent expirations.
Still, the company's pipeline looks likely to support ongoing growth.
10 stocks we like better than Novartis ›
Novartis (NYSE: NVS) is a major Swiss drug company with a market capitalization of over $300 billion. Its focus areas are extensive, spanning oncology, immunology, neuroscience, respiratory care, and cardiovascular, renal, and metabolic diseases. With a strong operating history and a diversified business,
The pharmaceutical giant could be an attractive stock for more conservative investors. Let's dive in and take a closer look to see why.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Novartis has a lot to work with
Novartis is one of the world's largest healthcare companies. That alone doesn't make it worth buying, but it speaks to the scale of the business and its historical success. A company doesn't achieve this level of scale and industry dominance by accident. Management is doing something right, and the drugmaker has been operating at a high level for years.
A triangular yellow road sign says High Yield Low Risk.
Image source: Getty Images.
Notably, Novartis is currently offering investors an attractive 2.9% dividend yield. That is far above the 1.1% of the S&P 500 index and the 1.7% average for the pharmaceutical sector.
The dividend has been steadily increasing, though not annually, for over 20 years. Meanwhile, the payout ratio is around 45%, which is entirely reasonable. Notably, over the past two decades, the payout ratio has never exceeded 100%. Basically, this is a relatively high-yield pharmaceutical stock that has a pretty conservative dividend profile.
There are going to be ups and downs
So, from a big-picture perspective, Novartis is the kind of dividend stock that will let you sleep well at night. However, investors shouldn't ignore the fact that it operates in a highly technical and competitive industry. The drugs it develops also have limited patent-protection windows, so it has to innovate constantly. And right now, older drugs are losing share to generic competition, leading revenue to flatline.
Advertisement
However, the company has also highlighted five drugs that are advancing through the pipeline or are gaining new indications. Basically, Novartis looks well on its way to offsetting the future revenue losses that come with patent expirations. In the end, this is just the way the pharma industry works, and Novartis is used to navigating these ebbs and flows while rewarding dividend investors well for sticking around.
A core holding for conservative dividend investors
Novartis isn't likely to be an exciting stock. That's purposeful, as management is clearly trying to build a sustainable, industry-leading business. If you invest for income and don't want to worry about sleepless nights, this giant pharma stock could be the perfect addition to your diversified dividend-stock portfolio.
Should you buy stock in Novartis right now?
Before you buy stock in Novartis, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novartis wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $424,262!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,163,635!*
Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 22, 2026.
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Source: “AOL Money”
